JOHNSON & JOHNSON SERVICES, INC.

Lobbying for JOHNSON & JOHNSON SERVICES INC

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$2,480,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 8

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
Treasury, Dept of
U.S. Trade Representative (USTR)
Veterans Affairs, Dept of (VA)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 24

HR 1539
Medical Device Electronic Labeling Act
HR 929
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
S 266
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
HR 946
ORPHAN Cures Act
S 864
HELP Copays Act
HR 2214
DRUG Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
S 1954
Biosimilar Red Tape Elimination Act
HR 5526
Biosimilar Red Tape Elimination Act
HR 2527
Early Detection of Vision Impairments for Children Act of 2025
HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
HR 4282
Contact Lens Prescription Verification Modernization Act
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HRES 1301
Expressing support for the inaugural Heart Recovery Awareness Day on February 20, 2025.
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 2658
Medication Affordability and Patent Integrity Act
HR 1109
Litigation Transparency Act of 2025
HR 2675
Protecting Our Courts from Foreign Manipulation Act

Lobbying activity 9

Taxation/Internal Revenue Code

Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB

Veterans

Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program

Trade (domestic/foreign)

- Issues related to USMCA review and renegotiation

Health Issues

- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing

Budget/Appropriations

- Issues related to stroke care

- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees

Law Enforcement/Crime/Criminal Justice

Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding

Pharmacy

- Issues related to the SUPPORT Act

Science/Technology

Issues related to - artificial intelligence - data privacy - cybersecurity - robotics

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.